{
  "abstract": "A growing body of evidence supports the use of glucagon-like peptide-1 (GLP-1) agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Phase III data demonstrate that once weekly subcutaneous semaglutide (trade names including Ozempic and Wegovy) at a dose of 2.4 mg reduces both steatohepatitis and liver fibrosis in patients with MASLD .1 Tirzepatide (Mounjaro or Zepbound) is a GLP-1/gastric-inhibitory peptide coagonist. Phase II data show tirzepatide is effective in resolving steatohepatitis in patients with MASLD with fibrosis at 52 weeks.2 However, no real-world data exist investigating the use of tirzepatide in patients with type 2 diabetes mellitus (T2DM) and MASLD to understand the impact on both their diabetic control and underlying liver disease.3",
  "authors": [
    {
      "affiliations": [
        "Department of Diabetes, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Rachel Halley"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Callum James Riley"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Jill Johnson"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Maria Round"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Julian Yeh"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Sheeba Khan"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Alex Boyd"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Geoffrey Haydon"
    },
    {
      "affiliations": [
        "Department of Diabetes, Queen Elizabeth Hospital Birmingham, Birmingham, UK",
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Samiul Mostafa"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK",
        "Roger Williams Institute of Hepatology, King’s College London, London, UK"
      ],
      "name": "Philip Newsome"
    },
    {
      "affiliations": [
        "Liver Unit, Queen Elizabeth Hospital Birmingham, Birmingham, UK"
      ],
      "name": "Matthew Armstrong"
    }
  ],
  "title": "Use of the dual GLP-1/GIP coagonist, tirzepatide, in patients with advanced metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: real-world data",
  "uid": "f6233a2e-2524-5a25-8e44-31e3e67a2f74"
}